New engineered peptides may show potential for long-lasting anti-HIV potential

Photo: Bi W, et al(2019)study, the researchers noted that IBP-CP24 can show a longer half-life, while also potentially carrying the activity of anti-HIV-1, even for drug-resistant strainsEnvevetide is the first anti-HIV peptide drug approved by the FDA, however, because of its short half-life and resistance to the HIV strain, the clinical application of the drug is often very limitedIn this study, researchers have developed a new strategy that can extend the half-life of the peptide by incorporating an anti-HIV short peptide called CP24 into a human immunoglobulin G (IgG) Fc binding peptide (IBP)IBP-CP24 inhibits the broad-spectrum HIV-1 strain, including the strain resistant to envehetin; Mice who received IBP-CP24 in advance were also protected from HIV-1 infection, and injecting both IBP-CP24 and normal human IgG into mice with chronic HIV-1 infection significantly reduced the level of the virus in the blood of the mouse bodymore interesting, combining IBP-CP24 with broad-spectrum HIV neutralizing antibodies can reveal a synergistic anti-HIV-1 effect, suggesting that this strategy may help reduce the dose of antibodies and peptides, while also reducing the cost of treatment in patientsoriginal origin:Wenwen Bi, Wei Xu, Liang Cheng, et alIgG Fc-binding motif-conjugated HIV-1 fusion exhibits siud potency and vivo half-life: Potential application in combination neutral nodPLoS Pathog 2019,15 (12): e1008082doi: 10.1371/journal.ppat.1008082